Literature DB >> 10232689

The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up.

F Kronenberg1, U Neyer, K Lhotta, E Trenkwalder, M Auinger, A Pribasnig, T Meisl, P König, H Dieplinger.   

Abstract

Patients with end-stage renal disease treated by hemodialysis have a tremendous risk for cardiovascular complications that cannot be explained by traditional atherosclerosis risk factors. Lipoprotein(a) (Lp(a)), a risk factor for these complications in the general population, is significantly elevated in these patients. In this study, it was determined whether Lp(a) and/or the genetically determined apo(a) phenotype are risk predictors for the development of coronary artery disease in these patients. A cohort of 440 unselected hemodialysis patients were followed for a period of 5 yr independent of the cause of renal disease, duration of preceding treatment, and the preexistence of coronary artery disease at study entry. Coronary events defined as definite myocardial infarction, percutaneous transluminal coronary angioplasty, aortocoronary bypass, or a stenosis >50% in the coronary angiography were the main outcome measure. Sixty-six (15%) of the 440 patients suffered a coronary event during follow-up. In univariate analysis, patients with events were significantly older and showed a trend to lower HDL cholesterol concentrations, and higher apolipoprotein B and Lp(a) concentrations without reaching significance. Apo(a) phenotypes of low molecular weight, however, were significantly more frequent in patients with compared to those without events (43.9% versus 21.9%, P<0.001). The other lipids, lipoproteins, and apolipoproteins were similar in both groups. Multiple Cox proportional hazards regression analysis found age and the apo(a) phenotype to be the best predictors for coronary events during the observation period, independent of whether patients with a preexisting coronary artery disease or an age >65 yr at the study entry or both were excluded from the analysis. Diabetes mellitus was a risk factor only in presence of a low molecular weight apo(a) phenotype. The genetically determined apo(a) phenotype is a strong and independent predictor for coronary events in hemodialysis patients. Apo(a) phenotyping might be helpful to identify hemodialysis patients at high risk for coronary artery disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10232689     DOI: 10.1681/ASN.V1051027

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  22 in total

1.  Incidence and risk factors of coronary heart disease in elderly patients on chronic hemodialysis.

Authors:  Lygeri P Soubassi; Theodore C Chiras; Emmanuel D Papadakis; George D Poulos; Dimitrios I Chaniotis; Ioannis P Tsapakidis; Sofia P Soubassi; Stylianos N Zerefos; Nikolaos S Zerefos; Dimitrios A Valis
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

Review 2.  Role of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney disease.

Authors:  Nosratola D Vaziri
Journal:  Clin Exp Nephrol       Date:  2013-08-24       Impact factor: 2.801

Review 3.  Causes and consequences of lipoprotein(a) abnormalities in kidney disease.

Authors:  Florian Kronenberg
Journal:  Clin Exp Nephrol       Date:  2013-10-16       Impact factor: 2.801

Review 4.  Structure, function, and genetics of lipoprotein (a).

Authors:  Konrad Schmidt; Asma Noureen; Florian Kronenberg; Gerd Utermann
Journal:  J Lipid Res       Date:  2016-04-13       Impact factor: 5.922

Review 5.  HDL in CKD-The Devil Is in the Detail.

Authors:  Florian Kronenberg
Journal:  J Am Soc Nephrol       Date:  2018-02-22       Impact factor: 10.121

6.  Enigmatic role of lipoprotein(a) in cardiovascular disease.

Authors:  Erdembileg Anuurad; Byambaa Enkhmaa; Lars Berglund
Journal:  Clin Transl Sci       Date:  2010-12       Impact factor: 4.689

Review 7.  Evidence-based statin prescription for cardiovascular protection in renal impairment.

Authors:  Fabio Fabbian; Alfredo De Giorgi; Marco Pala; Ruana Tiseo; Roberto Manfredini; Francesco Portaluppi
Journal:  Clin Exp Nephrol       Date:  2011-05-10       Impact factor: 2.801

Review 8.  ESRD-induced dyslipidemia-Should management of lipid disorders differ in dialysis patients?

Authors:  Hamid Moradi; Elani Streja; Nosratola D Vaziri
Journal:  Semin Dial       Date:  2018-04-29       Impact factor: 3.455

Review 9.  Genetic-epidemiological evidence on genes associated with HDL cholesterol levels: a systematic in-depth review.

Authors:  Eva Boes; Stefan Coassin; Barbara Kollerits; Iris M Heid; Florian Kronenberg
Journal:  Exp Gerontol       Date:  2008-11-17       Impact factor: 4.032

10.  Lipoprotein(a) level as a predictor of cardiovascular disease and small apoliprotein(a) isoforms in dialysis patients: assay-related differences are important.

Authors:  J Craig Longenecker; Josef Coresh; Michael J Klag; Neil R Powe; Nancy E Fink; Santica M Marcovina
Journal:  Clin Chim Acta       Date:  2008-07-18       Impact factor: 3.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.